In this video, Matthew J. Allaway, MD, assesses the differences between the transrectal and transperineal approaches to prostate biopsy and the overall advantage of the transperineal biopsy in detecting cancer and preventing infection. Allaway is the founder and president of Perinealogic, and a urologist and managing partner at Urology Associates, Cumberland, Maryland.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.